MET and non-small cell lung carcinoma: Amivantamab (JNJ-61186372) is a bispecific antibody that targets both EGFR and MET, demonstrating preclinical efficacy in EGFR-mutated NSCLC models and showing promise in a first-in-human study for advanced NSCLC [130].